GENERIC MEDICINES REGULATION IN BRAZIL
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 3
Abstract
The regulation of medicines in Brazil has proven to be one of the major concerns of government policies in recent decades. In order to improve access to quality medicines for the population, the National Drug Policy was instituted, culminating in the creation of the National Health Surveillance Agency (ANVISA) and the implementation of generic medicines policy. The generic medicines was effectively introduced in Brazil with the publication of the Law nº 9.787 in 1999, resulting from an objective of the Ministry of Health to significantly reduce the costs of pharmacological therapy, stimulate commercial competition and facilitate the population's access to drug treatment. In the same year the resolution no 391/1999 regarding the technical requirements for the registration of generics in Brazil was published. Since 1999, several legislation has been published in order to regulate the generic policy in Brazil. The present article summarises the legal framework for the implementation of the generic medicines in Brazil. It also describes the current technical requirements and legislation for the registration and maintenance of the register of generics in Brazil, according to ANVISA.
Authors and Affiliations
Priscila Aburachid Cardoso
Keywords
Related Articles
- EP ID EP326741
- DOI 10.22270/ijdra.v5i3.201
- Views 153
- Downloads 0
COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.
To waive a complete and systemic Bioequivalence (BE) study, Biowaiver or Request for a Biowaiver is a fast track approach to boost the drug development process. Over the past three-four years the Biowaiver market shows g...
INTERNATIONAL CONFERENCE ON HARMONISATION: AN OVERVIEW
The International Conference on Harmonisation (ICH) is a project that makes together the regulatory bodies of Europe, Japan and the United States and professionals from the pharmaceutical domain in the three areas to dis...
FACTS ON DRUG REGULATIONS
The pharmaceutical products are very much driven by the drug regulation imposed by ministry of health in individual countries. The basic facts on regulations is that they are mandatory and noncompliant are punishable und...
CONDUCIVE ENVIROMENT FOR FOSTERING INDIA SPECIFIC INNOVATION: NEW MEDICAL DEVICE RULES 2017
The medical technology sector in India valued at approximately $ 10 billion in 2015 at end consumer prices and is growing at 10-12 percent annually. Currently, the Indian medical devices industry represents just over 2 p...
FORMULATION AND EVALUATION OF NANOSUSPENSION OF ROSUVASTATIN CALCIUM
Poor water solubility and slow dissolution rate are issues for majority of upcoming and existing biologically active compounds. The aim of present work was to increase the dissolution rate of Rosuvastatin Calcium, a poor...